The Ohio State University

Ohio State Innovation Foundation

Natural Pharmaceuticals, Inc.

Phyton Holdings, LLC

Dasheng Wang

Ching-Shih Chen

Samuel K Kulp

Hao-Chieh Chiu

Larry Schlesinger

John S Gunn

James H Johnson

John C Byrd

James Harvey Johnson

Rex T Gallagher

Natarajan Muthusamy

John S Juchum

Jing-Ru Weng

Jian Yang

Jian Wang

Rex T Gallegher

Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.

Glucose transporter inhibitors

A method of treating infection byin a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described.The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.

Anti-staphylococcal celecoxib derivatives

A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is &#x2014;CF, Ar is selected from and R is selected from  

Anti-infective agents against intracellular pathogens

Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.

Protein phosphatase 2A-activating agents

Vitamin E succinate derivatives according to formula I: are described. These compounds can be included in pharmaceutical compositions, and can be used for the treatment of cancers such as metastatic cancer and as antiadhesive agents.

Antiadhesion agents

A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein Ris independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; Ris independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; Ris independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.

FTY720-derived anticancer agents

A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is &#x2014;CF, Ar is selected from and R is selected from where 

Compounds of the thiazolidinedione family are provided and shown to be effective androgen receptor ablative agents that can be used in methods of treating or preventing cancer or precancer, including prostate cancer. Also provided are methods of treating or preventing cancer by administering a therapeutically effective amount of one of the androgen receptor ablative agents to a subject in need of such treatment.

Androgen receptor-ablative agents

Compounds and methods for treating cancer and inducing apoptosis in unwanted rapidly proliferating cells. The compounds are shown in formula I: wherein X is hydroxyl or amino; Y is carboxyl or sulfonyl; R, R, R, and Rcan be the same or different and are selected from hydrogen, halogen, methoxy, trifluoromethyl, hydroxyl and combinations thereof, R, R, and Rmay be the same or different and are selected from hydrogen, chloro, bromo, nitro, phenyl, amino, methoxy, and combinations thereof, and derivatives or metabolites thereof.

Potent indole-3-carbinol-derived antitumor agents

The invention relates to methods and compositions for converting taxane amides to paclitaxel or other taxanes. In one alternative embodiment, the present invention comprises; (i) selectively protecting at least one OH group of a taxane amide; (ii) contacting the taxane amide with a transition metal compound to reduce the amide; (iii) contacting the reduced amide with an agent capable of substantially removing the transition metal; (iv) contacting the reduced amide with a hydrolyzing amount of acid to form a taxane amine salt in solution; (v) adding a sufficient amount of solvent to solidify the amine salt; and (vi) converting the taxane amine salt into paclitaxel or other taxanes.

Growing community of inventors

Dublin, OH, United States of America

Dasheng Wang